Applications of TALENs and CRISPR/Cas9 in Human Cells and Their Potentials for Gene Therapy

被引:33
|
作者
Niu, Jingwen [1 ,2 ]
Zhang, Bin [1 ,2 ]
Chen, Hu [1 ,2 ]
机构
[1] Acad Mil Med Sci, Dept Hematopoiet Stem Cell Transplantat, Affiliated Hosp, Beijing 100071, Peoples R China
[2] Acad Mil Med Sci, Cell & Gene Therapy Ctr, Beijing 100071, Peoples R China
关键词
TALENs; CRISPR/Cas9; Genome editing; Gene therapy; CCR5; NUCLEASES; CAS9; SPECIFICITY; EFFICIENT; TRANSCRIPTION; NICKING; STEM; GENERATION; RESISTANCE; CONVERSION;
D O I
10.1007/s12033-014-9771-z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The newly developed TALENs and emerging CRISPR/Cas9 have spurred interests in the field of genome engineering because of their ease of customization and high-efficient site-specific cleavages. Although these novel technologies have been successfully used in many types of cells, it is of great importance to apply them in human-derived cells to further observe and evaluate their clinical potentials in gene therapy. Here, we review the working mechanism of TALEN and CRISPR/Cas9, their effectiveness and specificity in human cells, and current methods to enhance efficiency and reduce off-target effects. Besides, CCR5 gene was chosen as a target example to illustrate their clinical potentials. Finally, some questions are raised for future research and for researchers to consider when making a proper choice bases on different purposes.
引用
收藏
页码:681 / 688
页数:8
相关论文
共 50 条
  • [31] Genome engineering via TALENs and CRISPR/Cas9 systems: challenges and perspectives
    Mahfouz, Magdy M.
    Piatek, Agnieszka
    Stewart, Charles Neal, Jr.
    PLANT BIOTECHNOLOGY JOURNAL, 2014, 12 (08) : 1006 - 1014
  • [32] Precise gene deletion and replacement using the CRISPR/Cas9 system in human cells
    Zheng, Qiupeng
    Cai, Xiaohong
    Tan, Meng How
    Schaffert, Steven
    Arnold, Christopher P.
    Gong, Xue
    Chen, Chang-Zheng
    Huang, Shenglin
    BIOTECHNIQUES, 2017, 62 (01) : xxii
  • [33] Efficient Gene Disruption in Cultured Primary Human Endothelial Cells by CRISPR/Cas9
    Abrahimi, Parwiz
    Chang, William G.
    Kluger, Martin S.
    Qyang, Yibing
    Tellides, George
    Saltzman, W. Mark
    Pober, Jordan S.
    CIRCULATION RESEARCH, 2015, 117 (02) : 121 - 128
  • [34] Precise gene deletion and replacement using the CRISPR/Cas9 system in human cells
    Zheng, Qiupeng
    Cai, Xiaohong
    Tan, Meng How
    Schaffert, Steven
    Arnold, Christopher P.
    Gong, Xue
    Chen, Chang-Zheng
    Huang, Shenglin
    BIOTECHNIQUES, 2014, 57 (03) : 115 - 124
  • [35] Highly efficient gene inactivation by adenoviral CRISPR/Cas9 in human primary cells
    Voets, Olaf
    Tielen, Frans
    Elstak, Edo
    Benschop, Julian
    Grimbergen, Max
    Stallen, Jan
    Janssen, Richard
    van Marle, Andre
    Essrich, Christian
    PLOS ONE, 2017, 12 (08):
  • [36] Multiplexed CRISPR gene editing in primary human islet cells with Cas9 ribonucleoprotein
    Bevacqua, Romina J.
    Zhao, Weichen
    Merheb, Emilio
    Kim, Seung Hyun
    Marson, Alexander
    Gloyn, Anna L.
    Kim, Seung K.
    ISCIENCE, 2024, 27 (01)
  • [37] Modelling and remodelling: the use of CRISPR/Cas9 and TALENs to create and modify mouse models of human disease
    Low, Benjamin
    Avery, Cindy
    Akiyama, Kouyou
    Wiles, Michael
    TRANSGENIC RESEARCH, 2014, 23 (05) : 908 - 908
  • [38] Applications of CRISPR/Cas9 for Gene Editing in Hereditary Movement Disorders
    Im, Wooseok
    Moon, Jangsup
    Kim, Manho
    JOURNAL OF MOVEMENT DISORDERS, 2016, 9 (03) : 136 - 143
  • [39] Applications of CRISPR/Cas9 in Reproductive Biology
    Khan, Faheem Ahmed
    Pandupuspitasari, Nuruliarizki Shinta
    Huang ChunJie
    Ahmad, Hafiz Ishfaq
    Kai Wang
    Ahmad, Muhammad Jamil
    Zhang, ShuJun
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2018, 26 : 94 - 102
  • [40] CRISPR/Cas9 System and its Research Progress in Gene Therapy
    Liu, Wenlou
    Yang, Chunsheng
    Liu, Yanqun
    Jiang, Guan
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (16) : 1912 - 1919